Establishment Labs price target lowered to $74 from $81 at Citi
Citi lowered the firm’s price target on Establishment Labs (ESTA) to $74 from $81 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Read More on ESTA:
- Establishment Labs Earnings Call Signals Profitable Growth
- Establishment Labs price target raised to $90 from $85 at Canaccord
- Establishment Labs price target raised to $90 from $85 at Stephens
- Establishment Labs price target raised to $95 from $88 at TD Cowen
- Establishment Labs price target raised to $100 from $90 at Mizuho
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hindalco misses profit estimates as Novelis disruptions weigh
Congress Revives US Bitcoin Reserve Idea – With a 20-Year Hold
Dow Jones Industrial Average shrugs off a hawkish new Fed chair to set a record
Black Swan Capitalist: What Will Trigger XRP Repricing Revealed
Trending news
MoreCrypto prices
More
